,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et12AF'}, 'Id': 'a0POZ00000M7Et12AF', 'Event_Date__c': '2018-09-03', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWGQA0'}, 'change': None}]",Sep 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'Application received from Shire following the call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting.', 'fs': 'Application received from Shire following the call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et22AF'}, 'Id': 'a0POZ00000M7Et22AF', 'Event_Date__c': '2018-09-25', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'Application received from Shire following the call for applications for medicines for rare disorders. To be considered at November 2018 Rare Disorders Subcommittee meeting.', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXuQAK'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that the application for teduglutide be declined based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns.', 'fs': 'The Subcommittee recommended that the application for teduglutide be declined based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et32AF'}, 'Id': 'a0POZ00000M7Et32AF', 'Event_Date__c': '2018-11-05', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Subcommittee recommended that the application for teduglutide be declined based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns.', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArZDQA0'}, 'change': None}, {'Summary': {'s': 'PTAC accepted the recommendation of the Rare Disorders Subcommittee that this funding application be declined.', 'fs': 'PTAC accepted the recommendation of the Rare Disorders Subcommittee that this funding application be declined.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et42AF'}, 'Id': 'a0POZ00000M7Et42AF', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'PTAC accepted the recommendation of the Rare Disorders Subcommittee that this funding application be declined.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArazQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et62AF'}, 'Id': 'a0POZ00000M7Et62AF', 'Event_Date__c': '2023-02-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDV7QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'fs': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et72AF'}, 'Id': 'a0POZ00000M7Et72AF', 'Event_Date__c': '2023-02-28', 'Event_Description__c': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDcRQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> teduglutide be listed with a <strong>medium</strong> <strong>priority</strong> for the treatment of adults with short bowel syndrome and intestinal failure within the context of treatment of gastrointestinal disease subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has short bowel syndrome with Type III intestinal failure due to major intestinal resection; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is over the age of 18; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a history of dependence on parenteral support for at least 12 months; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient requires at least three days a week of parenteral support; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient must be stable on their parenteral support regimen for at least four consecutive weeks before initiating teduglutide treatment; and</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to benefit from treatment; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a quantitative reduction in parenteral nutrition caloric requirements from baseline by week 26 of treatment; and a 25% reduction of PN caloric requirements from baseline by week 52 of treatment</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making these recommendations, the Advisory Committee considered: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health needs of individuals with SBS-IF reliant on parenteral nutrition, and the high health needs of their whānau</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the evidence from trial data demonstrating long term efficacy and safety of teduglutide in both adults and children</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential to achieve enteral autonomy from parenteral feeding when treated with teduglutide, particularly for children with SBS-IF</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high cost and poor incremental cost effectiveness of teduglutide in adults with SBS-IF </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential for high wastage of teduglutide, especially when used in children.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> teduglutide be listed with a <strong>medium</strong> <strong>priority</strong> for the treatment of adults with short bowel syndrome and intestinal failure within the context of treatment of gastrointestinal disease subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has short bowel syndrome with Type III intestinal failure due to major intestinal resection; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is over the age of 18; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a history of dependence on parenteral support for at least 12 months; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient requires at least three days a week of parenteral support; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient must be stable on their parenteral support regimen for at least four consecutive weeks before initiating teduglutide treatment; and</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to benefit from treatment; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a quantitative reduction in parenteral nutrition caloric requirements from baseline by week 26 of treatment; and a 25% reduction of PN caloric requirements from baseline by week 52 of treatment</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making these recommendations, the Advisory Committee considered: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health needs of individuals with SBS-IF reliant on parenteral nutrition, and the high health needs of their whānau</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the evidence from trial data demonstrating long term efficacy and safety of teduglutide in both adults and children</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential to achieve enteral autonomy from parenteral feeding when treated with teduglutide, particularly for children with SBS-IF</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high cost and poor incremental cost effectiveness of teduglutide in adults with SBS-IF </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential for high wastage of teduglutide, especially when used in children.</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding teduglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF) on Māori health areas of focus and Māori health outcomes. The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>).\xa0The Committee noted that the abstract reported that Māori children were marginally overrepresented accounting for 28% of the population cohort respectively, compared to 26% of the New Zealand paediatric population.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it reviewed an application for teduglutide for SBS-IF in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a> where it recommended that the application be declined, based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns. The Committee noted that PTAC reviewed the record from the Subcommittee meeting in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, where it accepted the Subcommittee recommendation that the application be declined.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in 2021, additional correspondence was received from the supplier providing further information for consideration and outlining the need for teduglutide for individuals with SBS-IF. The Committee noted that additional applications had also been received from Te Whatu Ora (endorsed by the New Zealand National Intestinal Failure &amp; Rehabilitation Service) regarding evidence for the use of teduglutide in children. The Committee also noted that Pharmac had received additional supporting evidence from NPPA applications.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, at the time of the November 2018 meeting, teduglutide was not approved by Medsafe, but has been subsequently approved for use in adults.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF can result from a variety of underlying causes (such as injury, vascular disease, cancer, resection, Crohn’s disease) which leads to a highly heterogenous population of individuals with SBS-IF with differing residual bowel anatomy, comorbidities, and clinical management requirements.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF results from a drastically reduced length of small intestine (to &lt;200cm) and that individuals with SBS-IF experience a range of symptoms including diarrhoea, nutrient deficiencies, weight loss, electrolyte disturbances, dehydration, and malnutrition. The Committee noted that individuals with SBS-IF are reliant on ongoing parenteral support for survival with the requirement to be hooked-up via intravenous line to an infusion pump for an average of 12 hour per day, five times per week. The Committee noted that this has substantial quality of life impacts for individuals with SBS-IF in relation to their sleep, and ability to work and socialise.\xa0</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, with current standard of care, only half of individuals on parenteral support survive more than ten years due to the development of life-threatening complications (such as sepsis, blood clots, or liver damage) associated with parenteral support and intravenous feeding.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that whānau and caregivers of individuals with SBS-IF also face substantial quality of life impacts as they need to devote physical, emotional and financial resources to caring for their family member with SBS-IF. The Committee noted that whānau often have to take time off work or other obligations in order to offer care, assist with preparing and administering intravenous feeding, assisting with physical hygiene, and transport to medical appointments. The Committee noted that whānau of individuals receiving parenteral support report a lack of social activities, disrupted familial and other relationships, lost friendships, withdrawal of external support, and repeated episodes of depression.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>). The Committee noted that the abstract reported that 56% of the group reported were male, 44% had been born preterm, and that Pacific and Māori children were marginally overrepresented accounting for 13% and 28% of the population cohort respectively, compared to 9% and 26% of the New Zealand paediatric population.</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that people with IF living in areas of high New Zealand socioeconomic deprivation were overrepresented, with 36% in the highest deprivation quintile and 9% in the least deprived quintile, compared to 24% and 19% respectively of the New Zealand paediatric population. The Committee noted that, in the abstract, SBS caused IF in 18% of cases, although for preterm neonates the prevalence of short bowel syndrome was higher (36%).</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following recommendations from other jurisdictions regarding the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1"">1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The PBAC (Australia) recommended that teduglutide be funded for adults with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/teduglutide-psd-march-2019.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>, noting the high clinical need and the possibility that teduglutide may reduce the burden associated with parenteral support. The PBAC then recommended that teduglutide be funded for children with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2021-03/files/teduglutide-psd-mar-2021.pdf"" target=""_blank"" style=""color: windowtext;"">2021</a> noting that the restriction should not specify any age criteria given teduglutide has been studied in paediatric individuals and was shown to be well tolerated. The PBAC noted that input from a paediatric advisory board formed the basis of, and justification for the submission’s request to include a 20% reduction in weekly parenteral support volume as a response criterion for paediatric individuals.</p><p class=""ql-indent-1"">1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The CDEC (Canada) recommended in <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0459_Revestive_complete_Jul-29_16.pdf"" target=""_blank"" style=""color: windowtext;"">2016</a> that teduglutide be funded for adults with SBS-IF, and extended its recommendation to include children (<a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0606%20Revestive%20-%20CDEC%20Final%20Recommendation%20November%2021%2C%202019_For%20posting.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>) aged one year and above who are dependent on parenteral support.</p><p class=""ql-indent-1"">1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The SMC (Scotland) recommended teduglutide for restricted use in NHS Scotland for individuals one to 17 years with SBS in <a href=""https://www.scottishmedicines.org.uk/media/3273/teduglutide-revestive-final-jan-2018-revised-060318-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2018</a>, and extended this recommendation to include funding for adults in <a href=""https://www.scottishmedicines.org.uk/media/5054/teduglutide-revestive-resub-final-jan-2020-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2020</a>.</p><p class=""ql-indent-1"">1.10.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>NICE (Wales/UK) recommended funding of teduglutide as an option for treating short bowel syndrome (SBS) in people 1 year and above in <a href=""https://www.nice.org.uk/guidance/ta804/resources/teduglutide-for-treating-short-bowel-syndrome-pdf-82613249888965"" target=""_blank"" style=""color: windowtext;"">2022</a>. NICE noted that clinical trial evidence showed that teduglutide reduces the number of days a week people with SBS require parenteral support compared with placebo, however, how much it reduces this is uncertain because the trial design may not reflect clinical practice.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary evidence available at the time of the November 2018 assessment of teduglutide for SBS-IF came from the STEPS randomised phase III clinical trial of teduglutide versus placebo in adults with SBS-IF with dependency on parenteral support at least three times per week (<a href=""https://pubmed.ncbi.nlm.nih.gov/22982184/"" target=""_blank"">Jeppesen et al. Gastroenterology. 2012;143:1473-1481</a>). The Committee noted that, in this trial, teduglutide offered at 33% improvement in response (measured as ≥20% reduction in parenteral support requirement) over placebo. The Committee noted that 54% of participants in the teduglutide treatment arm had a ≥1 day reduction in weekly parenteral nutrition requirements versus 23% with placebo. The Committee noted that there was minimal difference in treatment emergent adverse events between treatment arms, and that the most common treatment emergent adverse events in the teduglutide treatment arm were abdominal pain, nausea, gastrointestinal stoma complications, and abdominal distension.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in the STEPS quality of life analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/23587733/"" target=""_blank"">Jeppesen et al. Clin Nutr. 2013;32:713-21</a>), parenteral support reduction was associated with statistically significant quality of life improvements compared to baseline, which were not seen in those treated with placebo. However, the Committee noted additional cohort studies and randomised controlled trials (listed below) that indicated no impact of teduglutide on quality of life and so it was unclear from the published evidence if there was a meaningful quality of life improvement, particularly for a one-day reduced requirement for parenteral support. The Committee considered that one day less of parenteral support would not reduce the risks associated with intravenous feeding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted the STEPS-2 2-year open-label extension of the STEPS trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/26844839/"" target=""_blank"">Schwartz et al. Clin Transl Gastroenterol. 2016;7:e142</a>) signalling that positive results with teduglutide persisted.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted Study 004 (<a href=""https://pubmed.ncbi.nlm.nih.gov/21317170/"" target=""_blank"">Jeppesen et al. Gut. 2011;60:902-14</a>) and Study 005 (<a href=""https://pubmed.ncbi.nlm.nih.gov/23333663/"" target=""_blank"">O’Keefe et al. Clin Gastroneterol Hepatol. 2013;11:815-23</a>) investigating the effects of teduglutide at a dose of 0.10mg/kg and 0.05mg/kg compared to placebo in adults with SBS-IF needing parenteral support. The Committee noted that superiority of one dose of teduglutide over the other was not demonstrated. The Committee noted that nausea was an adverse event commonly associated with teduglutide.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an additional trial published since its previous consideration of teduglutide, <a href=""https://pubmed.ncbi.nlm.nih.gov/31495952/"" target=""_blank"">Kocoshis et al. JPEN J Parenter Enteral Nutr. 2020;44:621-31</a>:</p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>This was a phase III trial with 2 randomised, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm investigating the safety and efficacy teduglutide in paediatric patients with SBS-IF. Participants received 0.025 mg/kg (n=24) or 0.05 mg/kg (n=25) teduglutide once daily or SOC alone (n=9).</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The primary end point (≥20% reduction in parenteral support) was achieved by 13 (54.2%) in 0.025mg/kg/day arm, 18 (69.2%) in the tedulgutide 0.05 mg/kg/day arm, 18 (69.2%) in the 0.05 mg/kg/day arm, and 1 (11.1%) in the SOC arm (p &lt;0.05 vs. SOC). Both 0.025mg/kg and 0.05mg/kg teduglutide treated groups showed clinically significant reductions in parenteral support volume (P &lt; 0.05 vs SOC), parenteral support calories, days per week and hours per day of parenteral support infusions and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline.</p><p class=""ql-indent-1"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Two (8.3%, 0.025 mg/kg teduglutide) and three individuals (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. The most common treatment related adverse events were pyrexia and vomiting.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted a number of observational studies relating to the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33675349/"" target=""_blank"">Martin et al. Am J Clin Nutr. 2021;113:1343-50</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/full/10.1002/jpen.2095"" target=""_blank"">Allard et al. J Paranter Enteral Nutr. 2021;45 (S1):P25</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32391948/"" target=""_blank"">Puello et al. JPEN J Parenter Enteral Nutr. 2021;45:318-22</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(20)30285-0/fulltext"" target=""_blank"">Penvy et al. Clin Nutr ESPEN. 2020;40:436-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31932048/"" target=""_blank"">Joly et al. Clin Nutr. 2020;39:2856-62</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dialnet.unirioja.es/servlet/articulo?codigo=7669634"" target=""_blank"">Robles et al. Eur J Clin Pharm. 2020;3:166-70 (Abstract only)</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.gastrojournal.org/article/S0016-5085(19)41701-0/fulltext"" target=""_blank"">Chiplunker et al. Gastroenterology. 2020;158:Supplement S37</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/abs/10.1002/jpen.1983"" target=""_blank"">Solar et al. JPEN J Parenter Enteral Nutr. 2021;45:1072-82</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ueg.eu/library/a-specialty-pharmacy-cohort-study-evaluating-the-effectiveness-of-teduglutide-in-subgroups-of-short-bowel-syndrome-patients-receiving-parenteral-support-defined-by-bowel-anatomy/209817"" target=""_blank"">Chen et al. Unit Eur Gastroenterol J. 2019;7(S7.8):1012-4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>He et al. J Gastroen Hepatol. 2019;34(S2):194-5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regano et al. Nutrition. 2019;65(S):5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Abdullah et al. Gastroenterology. 2019;156(S1):S62</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ukleja et al. JPEN J Parenter Enteral Nutr. 2018;42:821-25</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ring et al. Expert Rev Gastroenterol Hepatol. 2018;12:257-64</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jpen.1011"" target=""_blank"">Lam et al. JPEN J Parenter Enteral Nutr. 2018;42:225-30</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30364471/"" target=""_blank"">Schoeler et al. Therap Adv.Gastroenterol. 2018;11:1756284818793343</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/O_03__A_Monocentric_Single_arm_Study_on_Long_term.4.aspx"" target=""_blank"">Lambe et al. Transplantation. 2021;105(7S):O-03</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34872727/"" target=""_blank"">Wong et al. J Pediatr Surg. 2022;57:143-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/36336350/"" target=""_blank"">Belza et al. JPEN J Parenter Enteral Nutr. 2022;online ahead of print</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_21__Achieving_Intestinal_Sufficiency__The.106.aspx"" target=""_blank"">Teran et al. Transplantation. 2021;105(7S):S59</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_37__Single_Center_Experience_with_Teduglutide_in.122.aspx"" target=""_blank"">Kinberg et al. Transplantation. 2021;105(S7):S67</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32804906/"" target=""_blank"">Boluda et al. J Pediatr Gastroenterol Nutr. 2020;71:734-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32868665/"" target=""_blank"">Hill S. J Pediatr Gastroenterol Nutr. 2020;71:697-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880479/"" target=""_blank"">Bioletto et al. Nutrients. 2022;14:796</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35811959/"" target=""_blank"">Falco et al. Front Nutr. 2022;9:866048</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(21)00113-3/fulltext"" target=""_blank"">Chen et al. Clin Nutr ESPEN. 2021;43:420-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004164/"" target=""_blank"">Chen et al. JPEN J Parenter Enteral Nutr. 2020;44:119-28</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29761915/"" target=""_blank"">Seidner et al. Nutr Clin Pract. 2018;33:520-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35774551/"" target=""_blank"">Gigola et al. Front Nutr. 2022;9:866518</a></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the studies ranged widely in quality and numbers of participants and considered that the data was highly heterogenous. The Committee noted that overall, teduglutide reduced the number of days of parenteral nutrition (and sometimes led to complete discontinuation of parenteral nutrition), and that ≥20% reduction in parenteral nutrition varied from 60-100% in the studies presented. The Committee also noted that abdominal pain, pyrexia and nausea were the most common adverse events relating to teduglutide, that stoma enlargement was often reported, that longer exposure on teduglutide resulted in a higher proportion of participants meeting study endpoints over 6 to 12 months of 40% to 70%, and that colorectal cancer was not increased with use of teduglutide but that the incidence of colon polyps increased.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that post hoc analysis of the STEPS and STEPS-2 trials by Chen et al. reported that having a stoma was a predictor of positive response, and that predictors of negative response were vascular disease, ileocecal valve presence, and being of female gender. The Committee also noted that those with inflammatory bowel disease, stoma, and without colon in continuity had a shorter time to response. The Committee considered that a reduction in parenteral nutrition has downstream intestinotrophic benefits and may reduce the risk of sepsis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of evidence for the use of teduglutide in the treatment of SBS-IF was moderate.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that individuals with SBS-IF are unlikely to have concerns regarding daily subcutaneous injection with teduglutide or frequent monitoring visits as these individuals are actively involved in their own treatment, well acquainted with the health system, and can often administer their own parenteral support from home.</p><h3><em style=""font-size: 14px;"">Cost and saving</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, although there is evidence that teduglutide may reduce the need for parenteral support, it would likely not eliminate the need for parenteral support in most patients. The Committee noted that the cost of teduglutide would be in addition to the cost of current treatment for the majority of individuals with SBS-IF. The Committee also considered that improvements in quality of life associated with teduglutide in the requested population are likely to be gained but noted that there is limited evidence of this in the currently published literature.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that one 5mg vial of teduglutide is adequate for an individual weighing up to 100kg and that the dose should be determined based on the weight of the individual receiving treatment. The Committee noted that the vial is for single use in one individual only and that any residue should be discarded, which would lead to substantial wastage of product, particularly in the paediatric setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the number of individuals who would access teduglutide under the suggested criteria is unknown but considered, based on the number of people accessing parenteral nutrition in New Zealand, that numbers are likely to be higher than proposed by the supplier in their 2018 submission. The Committee also considered that it was not clear if SBS-IF met the principles for a rare disorder.</p><h3><em style=""font-size: 14px;"">Funding criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the treatment of children with SBS-IF should be considered differently from the treatment of adults, and children are still growing and accommodating and do not have a static condition. The Committee considered that neonatal cases of SBS-IF where there was more than 25cm of small bowel remaining may be able to eventually achieve autonomy from parenteral feeding. The Committee considered that this scenario would be where treatment with teduglutide would have the most benefit in the reduction of long-term morbidities in these individuals. The Committee considered that those most at risk of intestinal failure and life-threatening complications in the paediatric population were pre-term babies, and those with growth restriction or complicated gastroschisis, all of which are more common in those with lower social determinants of health. The Committee noted again that there is some evidence for enteral autonomy in this population when treated with teduglutide, but that the evidence is not strong.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for teduglutide if it were to be funded in New Zealand for SBS-IF. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000M7Et8&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005PnN"" alt=""image.png""></img></p>', 'fs': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding teduglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF) on Māori health areas of focus and Māori health outcomes. The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>).\xa0The Committee noted that the abstract reported that Māori children were marginally overrepresented accounting for 28% of the population cohort respectively, compared to 26% of the New Zealand paediatric population.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it reviewed an application for teduglutide for SBS-IF in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a> where it recommended that the application be declined, based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns. The Committee noted that PTAC reviewed the record from the Subcommittee meeting in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, where it accepted the Subcommittee recommendation that the application be declined.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in 2021, additional correspondence was received from the supplier providing further information for consideration and outlining the need for teduglutide for individuals with SBS-IF. The Committee noted that additional applications had also been received from Te Whatu Ora (endorsed by the New Zealand National Intestinal Failure &amp; Rehabilitation Service) regarding evidence for the use of teduglutide in children. The Committee also noted that Pharmac had received additional supporting evidence from NPPA applications.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, at the time of the November 2018 meeting, teduglutide was not approved by Medsafe, but has been subsequently approved for use in adults.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF can result from a variety of underlying causes (such as injury, vascular disease, cancer, resection, Crohn’s disease) which leads to a highly heterogenous population of individuals with SBS-IF with differing residual bowel anatomy, comorbidities, and clinical management requirements.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF results from a drastically reduced length of small intestine (to &lt;200cm) and that individuals with SBS-IF experience a range of symptoms including diarrhoea, nutrient deficiencies, weight loss, electrolyte disturbances, dehydration, and malnutrition. The Committee noted that individuals with SBS-IF are reliant on ongoing parenteral support for survival with the requirement to be hooked-up via intravenous line to an infusion pump for an average of 12 hour per day, five times per week. The Committee noted that this has substantial quality of life impacts for individuals with SBS-IF in relation to their sleep, and ability to work and socialise.\xa0</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, with current standard of care, only half of individuals on parenteral support survive more than ten years due to the development of life-threatening complications (such as sepsis, blood clots, or liver damage) associated with parenteral support and intravenous feeding.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that whānau and caregivers of individuals with SBS-IF also face substantial quality of life impacts as they need to devote physical, emotional and financial resources to caring for their family member with SBS-IF. The Committee noted that whānau often have to take time off work or other obligations in order to offer care, assist with preparing and administering intravenous feeding, assisting with physical hygiene, and transport to medical appointments. The Committee noted that whānau of individuals receiving parenteral support report a lack of social activities, disrupted familial and other relationships, lost friendships, withdrawal of external support, and repeated episodes of depression.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>). The Committee noted that the abstract reported that 56% of the group reported were male, 44% had been born preterm, and that Pacific and Māori children were marginally overrepresented accounting for 13% and 28% of the population cohort respectively, compared to 9% and 26% of the New Zealand paediatric population.</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that people with IF living in areas of high New Zealand socioeconomic deprivation were overrepresented, with 36% in the highest deprivation quintile and 9% in the least deprived quintile, compared to 24% and 19% respectively of the New Zealand paediatric population. The Committee noted that, in the abstract, SBS caused IF in 18% of cases, although for preterm neonates the prevalence of short bowel syndrome was higher (36%).</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following recommendations from other jurisdictions regarding the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1"">1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The PBAC (Australia) recommended that teduglutide be funded for adults with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/teduglutide-psd-march-2019.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>, noting the high clinical need and the possibility that teduglutide may reduce the burden associated with parenteral support. The PBAC then recommended that teduglutide be funded for children with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2021-03/files/teduglutide-psd-mar-2021.pdf"" target=""_blank"" style=""color: windowtext;"">2021</a> noting that the restriction should not specify any age criteria given teduglutide has been studied in paediatric individuals and was shown to be well tolerated. The PBAC noted that input from a paediatric advisory board formed the basis of, and justification for the submission’s request to include a 20% reduction in weekly parenteral support volume as a response criterion for paediatric individuals.</p><p class=""ql-indent-1"">1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The CDEC (Canada) recommended in <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0459_Revestive_complete_Jul-29_16.pdf"" target=""_blank"" style=""color: windowtext;"">2016</a> that teduglutide be funded for adults with SBS-IF, and extended its recommendation to include children (<a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0606%20Revestive%20-%20CDEC%20Final%20Recommendation%20November%2021%2C%202019_For%20posting.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>) aged one year and above who are dependent on parenteral support.</p><p class=""ql-indent-1"">1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The SMC (Scotland) recommended teduglutide for restricted use in NHS Scotland for individuals one to 17 years with SBS in <a href=""https://www.scottishmedicines.org.uk/media/3273/teduglutide-revestive-final-jan-2018-revised-060318-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2018</a>, and extended this recommendation to include funding for adults in <a href=""https://www.scottishmedicines.org.uk/media/5054/teduglutide-revestive-resub-final-jan-2020-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2020</a>.</p><p class=""ql-indent-1"">1.10.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>NICE (Wales/UK) recommended funding of teduglutide as an option for treating short bowel syndrome (SBS) in people 1 year and above in <a href=""https://www.nice.org.uk/guidance/ta804/resources/teduglutide-for-treating-short-bowel-syndrome-pdf-82613249888965"" target=""_blank"" style=""color: windowtext;"">2022</a>. NICE noted that clinical trial evidence showed that teduglutide reduces the number of days a week people with SBS require parenteral support compared with placebo, however, how much it reduces this is uncertain because the trial design may not reflect clinical practice.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary evidence available at the time of the November 2018 assessment of teduglutide for SBS-IF came from the STEPS randomised phase III clinical trial of teduglutide versus placebo in adults with SBS-IF with dependency on parenteral support at least three times per week (<a href=""https://pubmed.ncbi.nlm.nih.gov/22982184/"" target=""_blank"">Jeppesen et al. Gastroenterology. 2012;143:1473-1481</a>). The Committee noted that, in this trial, teduglutide offered at 33% improvement in response (measured as ≥20% reduction in parenteral support requirement) over placebo. The Committee noted that 54% of participants in the teduglutide treatment arm had a ≥1 day reduction in weekly parenteral nutrition requirements versus 23% with placebo. The Committee noted that there was minimal difference in treatment emergent adverse events between treatment arms, and that the most common treatment emergent adverse events in the teduglutide treatment arm were abdominal pain, nausea, gastrointestinal stoma complications, and abdominal distension.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in the STEPS quality of life analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/23587733/"" target=""_blank"">Jeppesen et al. Clin Nutr. 2013;32:713-21</a>), parenteral support reduction was associated with statistically significant quality of life improvements compared to baseline, which were not seen in those treated with placebo. However, the Committee noted additional cohort studies and randomised controlled trials (listed below) that indicated no impact of teduglutide on quality of life and so it was unclear from the published evidence if there was a meaningful quality of life improvement, particularly for a one-day reduced requirement for parenteral support. The Committee considered that one day less of parenteral support would not reduce the risks associated with intravenous feeding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted the STEPS-2 2-year open-label extension of the STEPS trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/26844839/"" target=""_blank"">Schwartz et al. Clin Transl Gastroenterol. 2016;7:e142</a>) signalling that positive results with teduglutide persisted.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted Study 004 (<a href=""https://pubmed.ncbi.nlm.nih.gov/21317170/"" target=""_blank"">Jeppesen et al. Gut. 2011;60:902-14</a>) and Study 005 (<a href=""https://pubmed.ncbi.nlm.nih.gov/23333663/"" target=""_blank"">O’Keefe et al. Clin Gastroneterol Hepatol. 2013;11:815-23</a>) investigating the effects of teduglutide at a dose of 0.10mg/kg and 0.05mg/kg compared to placebo in adults with SBS-IF needing parenteral support. The Committee noted that superiority of one dose of teduglutide over the other was not demonstrated. The Committee noted that nausea was an adverse event commonly associated with teduglutide.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an additional trial published since its previous consideration of teduglutide, <a href=""https://pubmed.ncbi.nlm.nih.gov/31495952/"" target=""_blank"">Kocoshis et al. JPEN J Parenter Enteral Nutr. 2020;44:621-31</a>:</p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>This was a phase III trial with 2 randomised, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm investigating the safety and efficacy teduglutide in paediatric patients with SBS-IF. Participants received 0.025 mg/kg (n=24) or 0.05 mg/kg (n=25) teduglutide once daily or SOC alone (n=9).</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The primary end point (≥20% reduction in parenteral support) was achieved by 13 (54.2%) in 0.025mg/kg/day arm, 18 (69.2%) in the tedulgutide 0.05 mg/kg/day arm, 18 (69.2%) in the 0.05 mg/kg/day arm, and 1 (11.1%) in the SOC arm (p &lt;0.05 vs. SOC). Both 0.025mg/kg and 0.05mg/kg teduglutide treated groups showed clinically significant reductions in parenteral support volume (P &lt; 0.05 vs SOC), parenteral support calories, days per week and hours per day of parenteral support infusions and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline.</p><p class=""ql-indent-1"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Two (8.3%, 0.025 mg/kg teduglutide) and three individuals (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. The most common treatment related adverse events were pyrexia and vomiting.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted a number of observational studies relating to the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33675349/"" target=""_blank"">Martin et al. Am J Clin Nutr. 2021;113:1343-50</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/full/10.1002/jpen.2095"" target=""_blank"">Allard et al. J Paranter Enteral Nutr. 2021;45 (S1):P25</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32391948/"" target=""_blank"">Puello et al. JPEN J Parenter Enteral Nutr. 2021;45:318-22</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(20)30285-0/fulltext"" target=""_blank"">Penvy et al. Clin Nutr ESPEN. 2020;40:436-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31932048/"" target=""_blank"">Joly et al. Clin Nutr. 2020;39:2856-62</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dialnet.unirioja.es/servlet/articulo?codigo=7669634"" target=""_blank"">Robles et al. Eur J Clin Pharm. 2020;3:166-70 (Abstract only)</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.gastrojournal.org/article/S0016-5085(19)41701-0/fulltext"" target=""_blank"">Chiplunker et al. Gastroenterology. 2020;158:Supplement S37</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/abs/10.1002/jpen.1983"" target=""_blank"">Solar et al. JPEN J Parenter Enteral Nutr. 2021;45:1072-82</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ueg.eu/library/a-specialty-pharmacy-cohort-study-evaluating-the-effectiveness-of-teduglutide-in-subgroups-of-short-bowel-syndrome-patients-receiving-parenteral-support-defined-by-bowel-anatomy/209817"" target=""_blank"">Chen et al. Unit Eur Gastroenterol J. 2019;7(S7.8):1012-4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>He et al. J Gastroen Hepatol. 2019;34(S2):194-5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regano et al. Nutrition. 2019;65(S):5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Abdullah et al. Gastroenterology. 2019;156(S1):S62</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ukleja et al. JPEN J Parenter Enteral Nutr. 2018;42:821-25</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ring et al. Expert Rev Gastroenterol Hepatol. 2018;12:257-64</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jpen.1011"" target=""_blank"">Lam et al. JPEN J Parenter Enteral Nutr. 2018;42:225-30</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30364471/"" target=""_blank"">Schoeler et al. Therap Adv.Gastroenterol. 2018;11:1756284818793343</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/O_03__A_Monocentric_Single_arm_Study_on_Long_term.4.aspx"" target=""_blank"">Lambe et al. Transplantation. 2021;105(7S):O-03</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34872727/"" target=""_blank"">Wong et al. J Pediatr Surg. 2022;57:143-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/36336350/"" target=""_blank"">Belza et al. JPEN J Parenter Enteral Nutr. 2022;online ahead of print</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_21__Achieving_Intestinal_Sufficiency__The.106.aspx"" target=""_blank"">Teran et al. Transplantation. 2021;105(7S):S59</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_37__Single_Center_Experience_with_Teduglutide_in.122.aspx"" target=""_blank"">Kinberg et al. Transplantation. 2021;105(S7):S67</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32804906/"" target=""_blank"">Boluda et al. J Pediatr Gastroenterol Nutr. 2020;71:734-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32868665/"" target=""_blank"">Hill S. J Pediatr Gastroenterol Nutr. 2020;71:697-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880479/"" target=""_blank"">Bioletto et al. Nutrients. 2022;14:796</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35811959/"" target=""_blank"">Falco et al. Front Nutr. 2022;9:866048</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(21)00113-3/fulltext"" target=""_blank"">Chen et al. Clin Nutr ESPEN. 2021;43:420-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004164/"" target=""_blank"">Chen et al. JPEN J Parenter Enteral Nutr. 2020;44:119-28</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29761915/"" target=""_blank"">Seidner et al. Nutr Clin Pract. 2018;33:520-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35774551/"" target=""_blank"">Gigola et al. Front Nutr. 2022;9:866518</a></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the studies ranged widely in quality and numbers of participants and considered that the data was highly heterogenous. The Committee noted that overall, teduglutide reduced the number of days of parenteral nutrition (and sometimes led to complete discontinuation of parenteral nutrition), and that ≥20% reduction in parenteral nutrition varied from 60-100% in the studies presented. The Committee also noted that abdominal pain, pyrexia and nausea were the most common adverse events relating to teduglutide, that stoma enlargement was often reported, that longer exposure on teduglutide resulted in a higher proportion of participants meeting study endpoints over 6 to 12 months of 40% to 70%, and that colorectal cancer was not increased with use of teduglutide but that the incidence of colon polyps increased.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that post hoc analysis of the STEPS and STEPS-2 trials by Chen et al. reported that having a stoma was a predictor of positive response, and that predictors of negative response were vascular disease, ileocecal valve presence, and being of female gender. The Committee also noted that those with inflammatory bowel disease, stoma, and without colon in continuity had a shorter time to response. The Committee considered that a reduction in parenteral nutrition has downstream intestinotrophic benefits and may reduce the risk of sepsis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of evidence for the use of teduglutide in the treatment of SBS-IF was moderate.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that individuals with SBS-IF are unlikely to have concerns regarding daily subcutaneous injection with teduglutide or frequent monitoring visits as these individuals are actively involved in their own treatment, well acquainted with the health system, and can often administer their own parenteral support from home.</p><h3><em style=""font-size: 14px;"">Cost and saving</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, although there is evidence that teduglutide may reduce the need for parenteral support, it would likely not eliminate the need for parenteral support in most patients. The Committee noted that the cost of teduglutide would be in addition to the cost of current treatment for the majority of individuals with SBS-IF. The Committee also considered that improvements in quality of life associated with teduglutide in the requested population are likely to be gained but noted that there is limited evidence of this in the currently published literature.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that one 5mg vial of teduglutide is adequate for an individual weighing up to 100kg and that the dose should be determined based on the weight of the individual receiving treatment. The Committee noted that the vial is for single use in one individual only and that any residue should be discarded, which would lead to substantial wastage of product, particularly in the paediatric setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the number of individuals who would access teduglutide under the suggested criteria is unknown but considered, based on the number of people accessing parenteral nutrition in New Zealand, that numbers are likely to be higher than proposed by the supplier in their 2018 submission. The Committee also considered that it was not clear if SBS-IF met the principles for a rare disorder.</p><h3><em style=""font-size: 14px;"">Funding criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the treatment of children with SBS-IF should be considered differently from the treatment of adults, and children are still growing and accommodating and do not have a static condition. The Committee considered that neonatal cases of SBS-IF where there was more than 25cm of small bowel remaining may be able to eventually achieve autonomy from parenteral feeding. The Committee considered that this scenario would be where treatment with teduglutide would have the most benefit in the reduction of long-term morbidities in these individuals. The Committee considered that those most at risk of intestinal failure and life-threatening complications in the paediatric population were pre-term babies, and those with growth restriction or complicated gastroschisis, all of which are more common in those with lower social determinants of health. The Committee noted again that there is some evidence for enteral autonomy in this population when treated with teduglutide, but that the evidence is not strong.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for teduglutide if it were to be funded in New Zealand for SBS-IF. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000M7Et8&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005PnN"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Advisory Committee reviewed updated information from the supplier for the use of <span style=""color: black;"">teduglutide</span> (Revestive) for the treatment of short bowel syndrome with type III intestinal failure (SBS-IF), originally reviewed by the Rare Disorders Subcommittee in 2018.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Advisory Committee reviewed updated information from the supplier for the use of <span style=""color: black;"">teduglutide</span> (Revestive) for the treatment of short bowel syndrome with type III intestinal failure (SBS-IF), originally reviewed by the Rare Disorders Subcommittee in 2018.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'fs': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et82AF'}, 'Id': 'a0POZ00000M7Et82AF', 'Event_Date__c': '2023-08-11', 'Event_Description__c': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Aug 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> teduglutide be listed with a <strong>medium</strong> <strong>priority</strong> for the treatment of adults with short bowel syndrome and intestinal failure within the context of treatment of gastrointestinal disease subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has short bowel syndrome with Type III intestinal failure due to major intestinal resection; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is over the age of 18; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a history of dependence on parenteral support for at least 12 months; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient requires at least three days a week of parenteral support; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient must be stable on their parenteral support regimen for at least four consecutive weeks before initiating teduglutide treatment; and</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal </strong><span style=""font-size: 9pt;"">– only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to benefit from treatment; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a quantitative reduction in parenteral nutrition caloric requirements from baseline by week 26 of treatment; and a 25% reduction of PN caloric requirements from baseline by week 52 of treatment</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making these recommendations, the Advisory Committee considered: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health needs of individuals with SBS-IF reliant on parenteral nutrition, and the high health needs of their whānau</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the evidence from trial data demonstrating long term efficacy and safety of teduglutide in both adults and children</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential to achieve enteral autonomy from parenteral feeding when treated with teduglutide, particularly for children with SBS-IF</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high cost and poor incremental cost effectiveness of teduglutide in adults with SBS-IF </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the potential for high wastage of teduglutide, especially when used in children.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Advisory Committee reviewed updated information from the supplier for the use of <span style=""color: black;"">teduglutide</span> (Revestive) for the treatment of short bowel syndrome with type III intestinal failure (SBS-IF), originally reviewed by the Rare Disorders Subcommittee in 2018.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding teduglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF) on Māori health areas of focus and Māori health outcomes. The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>).\xa0The Committee noted that the abstract reported that Māori children were marginally overrepresented accounting for 28% of the population cohort respectively, compared to 26% of the New Zealand paediatric population.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it reviewed an application for teduglutide for SBS-IF in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a> where it recommended that the application be declined, based on the modest evidence of short-term benefit provided by treatment, lack of long-term data, and safety concerns. The Committee noted that PTAC reviewed the record from the Subcommittee meeting in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, where it accepted the Subcommittee recommendation that the application be declined.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in 2021, additional correspondence was received from the supplier providing further information for consideration and outlining the need for teduglutide for individuals with SBS-IF. The Committee noted that additional applications had also been received from Te Whatu Ora (endorsed by the New Zealand National Intestinal Failure &amp; Rehabilitation Service) regarding evidence for the use of teduglutide in children. The Committee also noted that Pharmac had received additional supporting evidence from NPPA applications.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, at the time of the November 2018 meeting, teduglutide was not approved by Medsafe, but has been subsequently approved for use in adults.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF can result from a variety of underlying causes (such as injury, vascular disease, cancer, resection, Crohn’s disease) which leads to a highly heterogenous population of individuals with SBS-IF with differing residual bowel anatomy, comorbidities, and clinical management requirements.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that SBS-IF results from a drastically reduced length of small intestine (to &lt;200cm) and that individuals with SBS-IF experience a range of symptoms including diarrhoea, nutrient deficiencies, weight loss, electrolyte disturbances, dehydration, and malnutrition. The Committee noted that individuals with SBS-IF are reliant on ongoing parenteral support for survival with the requirement to be hooked-up via intravenous line to an infusion pump for an average of 12 hour per day, five times per week. The Committee noted that this has substantial quality of life impacts for individuals with SBS-IF in relation to their sleep, and ability to work and socialise.\xa0</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, with current standard of care, only half of individuals on parenteral support survive more than ten years due to the development of life-threatening complications (such as sepsis, blood clots, or liver damage) associated with parenteral support and intravenous feeding.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that whānau and caregivers of individuals with SBS-IF also face substantial quality of life impacts as they need to devote physical, emotional and financial resources to caring for their family member with SBS-IF. The Committee noted that whānau often have to take time off work or other obligations in order to offer care, assist with preparing and administering intravenous feeding, assisting with physical hygiene, and transport to medical appointments. The Committee noted that whānau of individuals receiving parenteral support report a lack of social activities, disrupted familial and other relationships, lost friendships, withdrawal of external support, and repeated episodes of depression.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an abstract of a study detailing information on children with intestinal failure using data from the New Zealand National Intestinal Failure Service registry (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2019/07002/P3A_01__The_first_three_years_of_the_New_Zealand.61.aspx"" target=""_blank"">Andrews et al. Transplantation.2019;103(7S2):S42</a>). The Committee noted that the abstract reported that 56% of the group reported were male, 44% had been born preterm, and that Pacific and Māori children were marginally overrepresented accounting for 13% and 28% of the population cohort respectively, compared to 9% and 26% of the New Zealand paediatric population.</p><p class=""ql-indent-1"">1.9.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that people with IF living in areas of high New Zealand socioeconomic deprivation were overrepresented, with 36% in the highest deprivation quintile and 9% in the least deprived quintile, compared to 24% and 19% respectively of the New Zealand paediatric population. The Committee noted that, in the abstract, SBS caused IF in 18% of cases, although for preterm neonates the prevalence of short bowel syndrome was higher (36%).</p><h3><em style=""font-size: 14px;"">Health benefit</em></h3><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following recommendations from other jurisdictions regarding the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1"">1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The PBAC (Australia) recommended that teduglutide be funded for adults with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-03/files/teduglutide-psd-march-2019.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>, noting the high clinical need and the possibility that teduglutide may reduce the burden associated with parenteral support. The PBAC then recommended that teduglutide be funded for children with SBS-IF in <a href=""https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2021-03/files/teduglutide-psd-mar-2021.pdf"" target=""_blank"" style=""color: windowtext;"">2021</a> noting that the restriction should not specify any age criteria given teduglutide has been studied in paediatric individuals and was shown to be well tolerated. The PBAC noted that input from a paediatric advisory board formed the basis of, and justification for the submission’s request to include a 20% reduction in weekly parenteral support volume as a response criterion for paediatric individuals.</p><p class=""ql-indent-1"">1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The CDEC (Canada) recommended in <a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0459_Revestive_complete_Jul-29_16.pdf"" target=""_blank"" style=""color: windowtext;"">2016</a> that teduglutide be funded for adults with SBS-IF, and extended its recommendation to include children (<a href=""https://www.cadth.ca/sites/default/files/cdr/complete/SR0606%20Revestive%20-%20CDEC%20Final%20Recommendation%20November%2021%2C%202019_For%20posting.pdf"" target=""_blank"" style=""color: windowtext;"">2019</a>) aged one year and above who are dependent on parenteral support.</p><p class=""ql-indent-1"">1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The SMC (Scotland) recommended teduglutide for restricted use in NHS Scotland for individuals one to 17 years with SBS in <a href=""https://www.scottishmedicines.org.uk/media/3273/teduglutide-revestive-final-jan-2018-revised-060318-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2018</a>, and extended this recommendation to include funding for adults in <a href=""https://www.scottishmedicines.org.uk/media/5054/teduglutide-revestive-resub-final-jan-2020-for-website.pdf"" target=""_blank"" style=""color: windowtext;"">2020</a>.</p><p class=""ql-indent-1"">1.10.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>NICE (Wales/UK) recommended funding of teduglutide as an option for treating short bowel syndrome (SBS) in people 1 year and above in <a href=""https://www.nice.org.uk/guidance/ta804/resources/teduglutide-for-treating-short-bowel-syndrome-pdf-82613249888965"" target=""_blank"" style=""color: windowtext;"">2022</a>. NICE noted that clinical trial evidence showed that teduglutide reduces the number of days a week people with SBS require parenteral support compared with placebo, however, how much it reduces this is uncertain because the trial design may not reflect clinical practice.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the primary evidence available at the time of the November 2018 assessment of teduglutide for SBS-IF came from the STEPS randomised phase III clinical trial of teduglutide versus placebo in adults with SBS-IF with dependency on parenteral support at least three times per week (<a href=""https://pubmed.ncbi.nlm.nih.gov/22982184/"" target=""_blank"">Jeppesen et al. Gastroenterology. 2012;143:1473-1481</a>). The Committee noted that, in this trial, teduglutide offered at 33% improvement in response (measured as ≥20% reduction in parenteral support requirement) over placebo. The Committee noted that 54% of participants in the teduglutide treatment arm had a ≥1 day reduction in weekly parenteral nutrition requirements versus 23% with placebo. The Committee noted that there was minimal difference in treatment emergent adverse events between treatment arms, and that the most common treatment emergent adverse events in the teduglutide treatment arm were abdominal pain, nausea, gastrointestinal stoma complications, and abdominal distension.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in the STEPS quality of life analysis (<a href=""https://pubmed.ncbi.nlm.nih.gov/23587733/"" target=""_blank"">Jeppesen et al. Clin Nutr. 2013;32:713-21</a>), parenteral support reduction was associated with statistically significant quality of life improvements compared to baseline, which were not seen in those treated with placebo. However, the Committee noted additional cohort studies and randomised controlled trials (listed below) that indicated no impact of teduglutide on quality of life and so it was unclear from the published evidence if there was a meaningful quality of life improvement, particularly for a one-day reduced requirement for parenteral support. The Committee considered that one day less of parenteral support would not reduce the risks associated with intravenous feeding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted the STEPS-2 2-year open-label extension of the STEPS trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/26844839/"" target=""_blank"">Schwartz et al. Clin Transl Gastroenterol. 2016;7:e142</a>) signalling that positive results with teduglutide persisted.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted Study 004 (<a href=""https://pubmed.ncbi.nlm.nih.gov/21317170/"" target=""_blank"">Jeppesen et al. Gut. 2011;60:902-14</a>) and Study 005 (<a href=""https://pubmed.ncbi.nlm.nih.gov/23333663/"" target=""_blank"">O’Keefe et al. Clin Gastroneterol Hepatol. 2013;11:815-23</a>) investigating the effects of teduglutide at a dose of 0.10mg/kg and 0.05mg/kg compared to placebo in adults with SBS-IF needing parenteral support. The Committee noted that superiority of one dose of teduglutide over the other was not demonstrated. The Committee noted that nausea was an adverse event commonly associated with teduglutide.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an additional trial published since its previous consideration of teduglutide, <a href=""https://pubmed.ncbi.nlm.nih.gov/31495952/"" target=""_blank"">Kocoshis et al. JPEN J Parenter Enteral Nutr. 2020;44:621-31</a>:</p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>This was a phase III trial with 2 randomised, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm investigating the safety and efficacy teduglutide in paediatric patients with SBS-IF. Participants received 0.025 mg/kg (n=24) or 0.05 mg/kg (n=25) teduglutide once daily or SOC alone (n=9).</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The primary end point (≥20% reduction in parenteral support) was achieved by 13 (54.2%) in 0.025mg/kg/day arm, 18 (69.2%) in the tedulgutide 0.05 mg/kg/day arm, 18 (69.2%) in the 0.05 mg/kg/day arm, and 1 (11.1%) in the SOC arm (p &lt;0.05 vs. SOC). Both 0.025mg/kg and 0.05mg/kg teduglutide treated groups showed clinically significant reductions in parenteral support volume (P &lt; 0.05 vs SOC), parenteral support calories, days per week and hours per day of parenteral support infusions and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline.</p><p class=""ql-indent-1"">1.15.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>Two (8.3%, 0.025 mg/kg teduglutide) and three individuals (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. The most common treatment related adverse events were pyrexia and vomiting.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee also noted a number of observational studies relating to the use of teduglutide in the treatment of SBS-IF:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33675349/"" target=""_blank"">Martin et al. Am J Clin Nutr. 2021;113:1343-50</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/full/10.1002/jpen.2095"" target=""_blank"">Allard et al. J Paranter Enteral Nutr. 2021;45 (S1):P25</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32391948/"" target=""_blank"">Puello et al. JPEN J Parenter Enteral Nutr. 2021;45:318-22</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(20)30285-0/fulltext"" target=""_blank"">Penvy et al. Clin Nutr ESPEN. 2020;40:436-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31932048/"" target=""_blank"">Joly et al. Clin Nutr. 2020;39:2856-62</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://dialnet.unirioja.es/servlet/articulo?codigo=7669634"" target=""_blank"">Robles et al. Eur J Clin Pharm. 2020;3:166-70 (Abstract only)</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.gastrojournal.org/article/S0016-5085(19)41701-0/fulltext"" target=""_blank"">Chiplunker et al. Gastroenterology. 2020;158:Supplement S37</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/abs/10.1002/jpen.1983"" target=""_blank"">Solar et al. JPEN J Parenter Enteral Nutr. 2021;45:1072-82</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://ueg.eu/library/a-specialty-pharmacy-cohort-study-evaluating-the-effectiveness-of-teduglutide-in-subgroups-of-short-bowel-syndrome-patients-receiving-parenteral-support-defined-by-bowel-anatomy/209817"" target=""_blank"">Chen et al. Unit Eur Gastroenterol J. 2019;7(S7.8):1012-4</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>He et al. J Gastroen Hepatol. 2019;34(S2):194-5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Regano et al. Nutrition. 2019;65(S):5</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Abdullah et al. Gastroenterology. 2019;156(S1):S62</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ukleja et al. JPEN J Parenter Enteral Nutr. 2018;42:821-25</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Ring et al. Expert Rev Gastroenterol Hepatol. 2018;12:257-64</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://aspenjournals.onlinelibrary.wiley.com/doi/10.1002/jpen.1011"" target=""_blank"">Lam et al. JPEN J Parenter Enteral Nutr. 2018;42:225-30</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30364471/"" target=""_blank"">Schoeler et al. Therap Adv.Gastroenterol. 2018;11:1756284818793343</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/O_03__A_Monocentric_Single_arm_Study_on_Long_term.4.aspx"" target=""_blank"">Lambe et al. Transplantation. 2021;105(7S):O-03</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34872727/"" target=""_blank"">Wong et al. J Pediatr Surg. 2022;57:143-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/36336350/"" target=""_blank"">Belza et al. JPEN J Parenter Enteral Nutr. 2022;online ahead of print</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_21__Achieving_Intestinal_Sufficiency__The.106.aspx"" target=""_blank"">Teran et al. Transplantation. 2021;105(7S):S59</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://journals.lww.com/transplantjournal/Fulltext/2021/07001/P_37__Single_Center_Experience_with_Teduglutide_in.122.aspx"" target=""_blank"">Kinberg et al. Transplantation. 2021;105(S7):S67</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32804906/"" target=""_blank"">Boluda et al. J Pediatr Gastroenterol Nutr. 2020;71:734-9</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32868665/"" target=""_blank"">Hill S. J Pediatr Gastroenterol Nutr. 2020;71:697-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880479/"" target=""_blank"">Bioletto et al. Nutrients. 2022;14:796</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35811959/"" target=""_blank"">Falco et al. Front Nutr. 2022;9:866048</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicalnutritionespen.com/article/S2405-4577(21)00113-3/fulltext"" target=""_blank"">Chen et al. Clin Nutr ESPEN. 2021;43:420-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004164/"" target=""_blank"">Chen et al. JPEN J Parenter Enteral Nutr. 2020;44:119-28</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29761915/"" target=""_blank"">Seidner et al. Nutr Clin Pract. 2018;33:520-7</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35774551/"" target=""_blank"">Gigola et al. Front Nutr. 2022;9:866518</a></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the studies ranged widely in quality and numbers of participants and considered that the data was highly heterogenous. The Committee noted that overall, teduglutide reduced the number of days of parenteral nutrition (and sometimes led to complete discontinuation of parenteral nutrition), and that ≥20% reduction in parenteral nutrition varied from 60-100% in the studies presented. The Committee also noted that abdominal pain, pyrexia and nausea were the most common adverse events relating to teduglutide, that stoma enlargement was often reported, that longer exposure on teduglutide resulted in a higher proportion of participants meeting study endpoints over 6 to 12 months of 40% to 70%, and that colorectal cancer was not increased with use of teduglutide but that the incidence of colon polyps increased.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that post hoc analysis of the STEPS and STEPS-2 trials by Chen et al. reported that having a stoma was a predictor of positive response, and that predictors of negative response were vascular disease, ileocecal valve presence, and being of female gender. The Committee also noted that those with inflammatory bowel disease, stoma, and without colon in continuity had a shorter time to response. The Committee considered that a reduction in parenteral nutrition has downstream intestinotrophic benefits and may reduce the risk of sepsis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the strength and quality of evidence for the use of teduglutide in the treatment of SBS-IF was moderate.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that individuals with SBS-IF are unlikely to have concerns regarding daily subcutaneous injection with teduglutide or frequent monitoring visits as these individuals are actively involved in their own treatment, well acquainted with the health system, and can often administer their own parenteral support from home.</p><h3><em style=""font-size: 14px;"">Cost and saving</em></h3><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, although there is evidence that teduglutide may reduce the need for parenteral support, it would likely not eliminate the need for parenteral support in most patients. The Committee noted that the cost of teduglutide would be in addition to the cost of current treatment for the majority of individuals with SBS-IF. The Committee also considered that improvements in quality of life associated with teduglutide in the requested population are likely to be gained but noted that there is limited evidence of this in the currently published literature.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that one 5mg vial of teduglutide is adequate for an individual weighing up to 100kg and that the dose should be determined based on the weight of the individual receiving treatment. The Committee noted that the vial is for single use in one individual only and that any residue should be discarded, which would lead to substantial wastage of product, particularly in the paediatric setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the number of individuals who would access teduglutide under the suggested criteria is unknown but considered, based on the number of people accessing parenteral nutrition in New Zealand, that numbers are likely to be higher than proposed by the supplier in their 2018 submission. The Committee also considered that it was not clear if SBS-IF met the principles for a rare disorder.</p><h3><em style=""font-size: 14px;"">Funding criteria</em></h3><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the treatment of children with SBS-IF should be considered differently from the treatment of adults, and children are still growing and accommodating and do not have a static condition. The Committee considered that neonatal cases of SBS-IF where there was more than 25cm of small bowel remaining may be able to eventually achieve autonomy from parenteral feeding. The Committee considered that this scenario would be where treatment with teduglutide would have the most benefit in the reduction of long-term morbidities in these individuals. The Committee considered that those most at risk of intestinal failure and life-threatening complications in the paediatric population were pre-term babies, and those with growth restriction or complicated gastroschisis, all of which are more common in those with lower social determinants of health. The Committee noted again that there is some evidence for enteral autonomy in this population when treated with teduglutide, but that the evidence is not strong.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for teduglutide if it were to be funded in New Zealand for SBS-IF. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000M7Et8&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005PnN"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000001LdU9YAK'}, 'change': None}]",Sep 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et92AF'}, 'Id': 'a0POZ00000M7Et92AF', 'Event_Date__c': '2023-12-03', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004A8GcYAK'}, 'change': None}]",Dec 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2019', 'fs': 'Apr 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7Et52AF'}, 'Id': 'a0POZ00000M7Et52AF', 'Event_Date__c': '2019-04-16', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Apr 2019', 'Status_History__c': 'a132P000000AreFQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000M7EtA2AV'}, 'Id': 'a0POZ00000M7EtA2AV', 'Event_Date__c': '2023-12-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004JtLGYA0'}, 'change': None}]",Apr 2019,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
